MARKET

SAVA

SAVA

Cassava Sciences
NASDAQ
2.750
+0.060
+2.23%
After Hours: 2.769 +0.019 +0.68% 19:58 01/17 EST
OPEN
2.720
PREV CLOSE
2.690
HIGH
2.780
LOW
2.660
VOLUME
2.08M
TURNOVER
--
52 WEEK HIGH
42.20
52 WEEK LOW
2.230
MARKET CAP
132.30M
P/E (TTM)
-7.2906
1D
5D
1M
3M
1Y
5Y
1D
Simufilam's Collapse Leaves Cassava Searching For A Viable Future
Seeking Alpha · 3d ago
Weekly Report: what happened at SAVA last week (0106-0110)?
Weekly Report · 5d ago
Cassava laying off one-third of staff to curb expenses
Seeking Alpha · 01/07 22:02
Cassava Sciences to reduce workforce by 33%
TipRanks · 01/07 21:41
Cassava Sciences Reveals Implementing Cost Curtailment Including Workforce Reduction Of Approximately 33%
Benzinga · 01/07 21:31
CASSAVA- TOPLINE DATA FROM PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXPECTED LATE Q1/EARLY Q2 2025
Reuters · 01/07 21:30
Cassava Sciences Provides a Business Update
Barchart · 01/07 15:30
Weekly Report: what happened at SAVA last week (1230-0103)?
Weekly Report · 01/06 10:39
More
About SAVA
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

Webull offers Cassava Sciences Inc stock information, including NASDAQ: SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.